AEGEAN Trial: Perioperative Approach in NSCLC

EP: 1.Treatment Approaches for Early-Stage Lung Cancer

EP: 2.Driving Precision Medicine Through Molecular Testing in NSCLC

EP: 3.Neoadjuvant/Perioperative Immunotherapy in NSCLC

EP: 4.Referral of Early-Stage NSCLC to Multidisciplinary Teams

EP: 5.Neoadjuvant, Adjuvant, and Perioperative Options in NSCLC

EP: 6.Updates in CheckMate-816 From ESMO 2023

Now Viewing

EP: 7.AEGEAN Trial: Perioperative Approach in NSCLC

EP: 8.Latest From the NEOTORCH Trial & KEYNOTE-671 Trial

EP: 9.CheckMate-77T Trial Results From ESMO 2023

EP: 10.Treatment Decision Making by Stage for Resectable NSCLC

EP: 11.The Emerging Role of ctDNA in NSCLC Management

EP: 12.Addressing Gaps in Care for Non-Small Cell Lung Cancer

This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.

Forde and Cascone discuss the AEGEAN study, a phase 3 trial that tested the combination of perioperative durvalumab, a PD-L1 inhibitor, with neoadjuvant platinum-based chemotherapy for patients with stage IA to IIIB non–small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer 8th edition staging system. The trial aimed to induce greater pathological responses, improve outcomes, and potentially trigger immunological memory by administering immunotherapy in the perioperative setting.

In the AEGEAN trial, patients received 4 cycles of neoadjuvant chemotherapy plus durvalumab, followed by 12 cycles of adjuvant durvalumab, compared with neoadjuvant chemotherapy alone followed by adjuvant placebo. The study demonstrated an improvement in event-free survival with a hazard ratio of 0.68 in favor of durvalumab, as well as an improvement in the pathological complete response rate (17.2%) compared with chemotherapy alone.

The different criteria used for pathological response assessment in the AEGEAN trial compared with other studies, such as CheckMate 816 (which reported a 24% pathological complete response rate), highlight the need for harmonization of these criteria as these therapies become the standard of care.

Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.